Research Analysts’ Recent Ratings Updates for Zenas BioPharma (ZBIO)

A number of firms have modified their ratings and price targets on shares of Zenas BioPharma (NASDAQ: ZBIO) recently:

• 10/13/2026 – Zenas BioPharma had its “buy” rating reaffirmed by HC Wainwright. They now have a $44.00 price target on the stock.
• 10/6/2026 – Zenas BioPharma had its “sell (e+)” rating reaffirmed by Weiss Ratings.
• 9/30/2026 – Zenas BioPharma had its price target raised by Citigroup Inc. from $41.00 to $48.00. They now have a “buy” rating on the stock.
• 9/30/2026 – Zenas BioPharma had its “buy” rating reaffirmed by Guggenheim. They now have a $55.00 price target on the stock.
• 9/30/2026 – Zenas BioPharma had its “outperform” rating reaffirmed by Wedbush. They now have a $45.00 price target on the stock.
• 9/30/2026 – Zenas BioPharma had its “buy” rating reaffirmed by HC Wainwright. They now have a $44.00 price target on the stock.

Zenas BioPharma, Inc is a clinical-stage biopharmaceutical company focused on developing immune-based therapies for patients with serious autoimmune diseases. The company’s research is centered on medicines designed to modulate the immune system while potentially avoiding the broad immune-cell depletion associated with some existing treatments.

Zenas’ lead product candidate is obexelimab, an investigational monoclonal antibody designed to bind CD19 and FcγRIIb receptors on B cells. Through this mechanism, obexelimab is intended to inhibit B-cell activity without eliminating the cells.